Mobile

A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects w...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003821-93

A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

-To evaluate the safety and tolerability of VX-661 monotherapy and VX-661/VX-770 cotherapy -To evaluate the effect of VX-661 monotherapy and VX-661/VX-770 cotherapy on CFTR function

Critère d'inclusion

  • Cystic fibrosis

Liens